A PHASE II TRIAL OF SGI-110 IN PATIENTS WITH IPSS HIGH AND INT 2 MYELODYSPLASTIC SYNDROME, ACUTE MYELOID LEUKEMIA WITH 20-30% MARROW BLASTS OR CHRONIC MYELOMONOCYTIC LEUKEMIA TYPE 2 NOT RESPONDING TO AZACITIDINE OR DECITABINE AFTER AT LEAST 6 COURSES OR RELAPSING AFTER A RESPONSE: